touchLearning Activities
On April 24, 2025, Brussels will host the 4th annual Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Awareness Day, organized by EUFOREA. This year’s theme, "New Ambitions of Care," focuses on enhancing understanding of CRSwNP, improving early diagnosis, and promoting better treatment strategies for those affected by this debilitating condition.
As part of our Future Leaders series, Dr. Shelby MacRae, a pulmonary and critical care specialist at LSUHSC, shares her journey from ICU intern to bronchiectasis and NTM researcher. She discusses challenges in care, lack of awareness, and future advances. Passionate about mentorship, she encourages future pulmonologists to find balance, build foundations, and stay driven by patient needs.
The current treatment landscape for severe asthma faces major challenges despite biologic advances targeting type 2 inflammation. Current biomarkers like BEC and FeNO inadequately predict treatment response. To optimize precision medicine, improved molecular phenotyping and novel non-invasive biomarkers are urgently needed to better identify asthma endotypes and guide therapy.
In this episode, Professor Irene Higginson, Director of Better Health and Care Futures at King’s College London, discusses the complex challenges of managing breathlessness. She explores non-pharmacological strategies, the value of multidisciplinary care, and how the Breathlessness Support Services at KCL are transforming patient support. Tune in for expert insights and a look at future directions in breathlessness research and care.
Brisbane, Australia, will host the 8th World Bronchiectasis Conference (WBC) from 14-17th July 2025, bringing together healthcare professionals, researchers and patients from around the globe to advance the understanding and treatment of bronchiectasis. The event is co-hosted by Lung Foundation Australia, the University of Queensland, and the Australian Bronchiectasis Consortium.
In this interview, Professor Juzar Ali, MD, FRCP(C), FCCP, a leading expert in respiratory medicine and LSU Alumni Klein Professor Emeritus of Medicine at Louisiana State University (LSU) Health Sciences Center in New Orleans, LA, USA, reflects on his distinguished career specializing in tuberculosis (TB), non-tuberculous mycobacterial disease (NTM) and bronchiectasis.
#AAAAI2025: Must-know Updates in Chronic Rhinosinusitis - Key Data from the AAAAI/WAO Joint Congress
The 2025 AAAAI and WAO joint congress highlighted advances in chronic rhinosinusitis (CRS) treatment. Notable studies presented positive results for novel biologic therapies, including tezepelumab, depemokimab and mepolizumab for chronic rhinosinusitis with nasal polyps (CRSwNP), and dupilumab for chronic rhinosinusitis without nasal polyps (CRSsNP). These findings highlight significant advancements in symptom management, offering hope for improved patient outcomes and reduced treatment burdens.
We are excited to welcome you to San Francisco for the ATS 2025 International Conference! Leaders, as well as emerging scientists and clinicians, who are at the forefront of medical breakthroughs and clinical innovation in pulmonary, critical care and sleep medicine will gather for networking and inspiring talks.
Boehringer Ingelheim has announced that its investigational drug, nerandomilast (BI 1015550), has successfully met the primary endpoint in the phase III FIBRONEERâ„¢-ILD study. The trial assessed the absolute change from baseline in forced vital capacity (FVC) [mL] at Week 52 compared ...
For patients living with chronic respiratory diseases (CRDs) such as chronic rhinosinusitis (CRS), asthma and chronic obstructive pulmonary disease (COPD), access to reliable and comprehensive health information is often limited and unreliable.
GSK has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application for depemokimab, an investigational monoclonal antibody targeting interleukin-5 (IL-5), for two indications: as an add-on maintenance treatment for asthma in patients aged 12 and older with type 2 inflammation characterized by an eosinophilic phenotype, and as an add-on treatment for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
As winter takes hold, the World Health Organisation (WHO) has begun sharing updates on pathogens and their impact across the Northern Hemisphere. This time of year is marked by a significant rise in acute respiratory infections (ARIs) and other common respiratory illnesses.
The results of a pivotal phase I/II study for PRGN-2012, an investigational gene therapy for recurrent respiratory papillomatosis (RRP), were recently published in The Lancet Respiratory Medicine.1 The study demonstrated that over 50% of participants achieved a complete response, requiring no surgical interventions for at least 12 months post-treatment. Additionally, the therapy showed a strong safety profile, with no dose-limiting toxicities reported. These findings form the basis of Precigen, Inc.’s Biologics License Application (BLA), which has been submitted to the U.S. Food and Drug Administration (FDA) along with a request for priority review. 1
A recent single-arm, phase 3 study (RIDGELINE VX21-121-105)1 published in The Lancet Respiratory Medicine2 has shown positive results for vanzacaftor–tezacaftor–deutivacaftor in treating paediatric cystic fibrosis (CF) patients, demonstrating improvements in lung function, sweat chloride levels and quality of life. This trial focused on children aged 6 to 11 years, a group often excluded from studies involving adults or older children, as well as key ages for CF treatment.
As 2024 comes to a close and as the new Patient Advisory Board & Advocacy Manager at EUFOREA, I have the privilege to reflect on the achievements and milestones of EUFOREA this year. With my background as a pharmacist and scientific ...
As 2024 draws to a close, we’re celebrating a fantastic year of content.
A recent phase 2 trial published in The Lancet Respiratory Medicine has demonstrated that benralizumab, a monoclonal antibody targeting interleukin-5 receptor-α, can significantly reduce treatment failure in eosinophilic exacerbations of asthma and COPD.
The International Primary Care Respiratory Group (IPCRG), is proud to host the 8th IPCRG Scientific Meeting in Brașov, Romania, on Friday 11 and Saturday 12 April 2025. This event, in partnership with the RespiRO team and the Transilvania University of Brașov promises to bring together researchers, innovators, and industry leaders to advance respiratory care in primary health settings.
touchRESPIRATORY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
